Abstract
Bioresorbable scaffolds (BRS) have emerged as a novel technology in interventional cardiology. However, recent trials demonstrate higher rates of scaffold thrombosis and device failure compared to conventional drug eluting stents. Limited Australian data on BRS outcomes are available. BRS
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
